{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T09:40:15Z","timestamp":1717580415514},"reference-count":59,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Epidemiological studies have demonstrated an increased risk of developing B-cell lymphomas in patients with chronic hepatitis C virus (HCV) infection. However, the strength of the association shows great geographic discrepancies, with higher relative risk in countries with high HCV prevalence. It remains unclear whether additional environmental and genetic factors are involved or if the international variability is simply a consequence of the variable infection prevalence. Therefore, a causal relationship remains controversial. Other confounding factors may affect the comparability of the different studies, including the method of HCV assessment, the selection of normal controls, the lymphoma classification used, and the year of publication. The most convincing proof is the observation, mainly limited to some indolent subtypes, of B-cell lymphoma regressions after HCV eradication with IFN and ribavirin. However, the molecular mechanisms of the HCV-induced lymphomagenesis are mainly hypothetical. According to the model considered to be most plausible, lymphoma growth is a consequence of the continuous antigenic stimulation of the B-cell immunologic response induced by the chronic viral infection. This review summarizes the current epidemiological and biological evidence of a role of HCV in lymphomagenesis, describing the putative mechanisms for a causative relationship. The clinical characteristics and management difficulties of the HCV-associated lymphomas are also discussed. HCV treatment with IFN cannot be given safely in concomitance with cytotoxic lymphoma treatment because of hematological and liver toxicity. However, novel and better tolerated antiviral regimens are under development and will hopefully make the treatment of both lymphoma and hepatitis easier in the future.<\/jats:p>","DOI":"10.1182\/asheducation-2014.1.590","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T18:39:03Z","timestamp":1416854343000},"page":"590-598","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Hepatitis C virus-associated B-cell non-Hodgkin lymphomas"],"prefix":"10.1182","volume":"2014","author":[{"given":"Barbara","family":"Vannata","sequence":"first","affiliation":[{"name":"Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[{"name":"Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111703295250700_B1","unstructured":"World Health Organization Hepatitis C: fact sheet number 164 Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/"},{"issue":"2","key":"2019111703295250700_B2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1017\/S0950268813000940","article-title":"Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association","volume":"142","author":"Hope","year":"2014","journal-title":"Epidemiol Infect"},{"key":"2019111703295250700_B3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1471-2334-12-S2-S2","article-title":"Chronic HCV infection: epidemiological and clinical relevance","volume":"12","author":"Zaltron","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2019111703295250700_B4","unstructured":"Centers for Disease Control and Prevention Hepatitis C information for health professionals Available from: http:\/\/www.cdc.gov\/hepatitis\/HCV\/index.htm"},{"key":"2019111703295250700_B5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","article-title":"A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt","volume":"31","author":"Sievert","year":"2011","journal-title":"Liver Int"},{"issue":"21","key":"2019111703295250700_B6","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","article-title":"A role for hepatitis C virus infection in type II cryoglobulinemia","volume":"327","author":"Agnello","year":"1992","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111703295250700_B7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.dld.2005.01.003","article-title":"Hepatitis C virus and non-Hodgkin's lymphoma 10 years later","volume":"37","author":"Mazzaro","year":"2005","journal-title":"Dig Liver Dis"},{"issue":"12","key":"2019111703295250700_B8","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1136\/jcp.2007.051870","article-title":"Hepatitis C virus and lymphoma","volume":"60","author":"Viswanatha","year":"2007","journal-title":"J Clin Pathol"},{"issue":"6","key":"2019111703295250700_B9","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood-2010-06-275818","article-title":"Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities","volume":"117","author":"Marcucci","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111703295250700_B10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3892\/ijo_00000618","article-title":"Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia?","volume":"36","author":"Libra","year":"2010","journal-title":"Int J Oncol"},{"issue":"1","key":"2019111703295250700_B11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archinte.165.1.101","article-title":"Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias","volume":"165","author":"Monti","year":"2005","journal-title":"Arch Intern Med"},{"issue":"9","key":"2019111703295250700_B12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1349-7006.2004.tb03256.x","article-title":"Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies","volume":"95","author":"Matsuo","year":"2004","journal-title":"Cancer Sci"},{"issue":"11","key":"2019111703295250700_B13","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-06-0308","article-title":"Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies","volume":"15","author":"Dal Maso","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"2019111703295250700_B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.20205","article-title":"B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review","volume":"111","author":"Negri","year":"2004","journal-title":"Int J Cancer"},{"issue":"3","key":"2019111703295250700_B15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3816\/CLM.2002.n.021","article-title":"Hepatitis C virus infection and B-cell non-Hodgkin's lymphomas: more than a simple association","volume":"3","author":"Musto","year":"2002","journal-title":"Clin Lymphoma"},{"issue":"6","key":"2019111703295250700_B16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1053\/j.gastro.2003.09.025","article-title":"Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis","volume":"125","author":"Gisbert","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"2019111703295250700_B17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cgh.2008.02.011","article-title":"Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium","volume":"6","author":"de Sanjose","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2019111703295250700_B18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ijc.20021","article-title":"Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study","volume":"111","author":"Engels","year":"2004","journal-title":"Int J Cancer"},{"issue":"18","key":"2019111703295250700_B19","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.297.18.2010","article-title":"Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus","volume":"297","author":"Giordano","year":"2007","journal-title":"JAMA"},{"issue":"6","key":"2019111703295250700_B20","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1053\/j.gastro.2006.09.019","article-title":"Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH","volume":"131","author":"Nieters","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"2019111703295250700_B21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jhep.2013.03.018","article-title":"Hepatitis C-associated B-cell non-Hodgkin lymphomas: epidemiology, molecular signature and clinical management","volume":"59","author":"Peveling-Oberhag","year":"2013","journal-title":"J Hepatol"},{"issue":"12","key":"2019111703295250700_B22","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjmed.2007.06.022","article-title":"Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C","volume":"120","author":"Kawamura","year":"2007","journal-title":"Am J Med"},{"issue":"2","key":"2019111703295250700_B23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdl388","article-title":"Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT","volume":"18","author":"Arcaini","year":"2007","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111703295250700_B24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1182\/blood.V90.2.776","article-title":"Characterization of Overt B-Cell Lymphomas in Patients With Hepatitis C Virus Infection","volume":"90","author":"De Vita","year":"1997","journal-title":"Blood"},{"issue":"6","key":"2019111703295250700_B25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2005.01.5016","article-title":"Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs","volume":"24","author":"Besson","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111703295250700_B26","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/annonc\/mdl131","article-title":"Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy","volume":"17","author":"Visco","year":"2006","journal-title":"Ann Oncol"},{"issue":"7","key":"2019111703295250700_B27","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/1042819031000083055","article-title":"Clinical features and outcome in HCV-positive aggressive non-Hodgkin's lymphoma","volume":"44","author":"Tomita","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111703295250700_B28","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3324\/haematol.2013.094318","article-title":"Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi","volume":"99","author":"Merli","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"2019111703295250700_B29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2009-10-248518","article-title":"Rituximab plus Peg-interferon-\u03b1\/ribavirin compared with Peg-interferon-\u03b1\/ribavirin in hepatitis C\u2013related mixed cryoglobulinemia","volume":"116","author":"Saadoun","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111703295250700_B30","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/annonc\/mdp454","article-title":"Subcutaneous \u2018lipoma-like\u2019 B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT","volume":"21","author":"Paulli","year":"2010","journal-title":"Ann Oncol"},{"issue":"7","key":"2019111703295250700_B31","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/1042819031000076972","article-title":"Hepatitis C virus (HCV) and lymphomagenesis","volume":"44","author":"Weng","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"2019111703295250700_B32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/1743-422X-10-346","article-title":"Detection of hepatitis C virus (HCV) negative strand RNA and NS3 protein in peripheral blood mononuclear cells (PBMC): CD3+, CD14+ and CD19+","volume":"10","author":"Pawelczyk","year":"2013","journal-title":"Virol J"},{"issue":"6","key":"2019111703295250700_B33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1159\/000317690","article-title":"Peripheral B cells may serve as a reservoir for persistent hepatitis C virus infection","volume":"2","author":"Ito","year":"2010","journal-title":"J Innate Immun"},{"issue":"5","key":"2019111703295250700_B34","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1128\/JVI.03081-12","article-title":"B cells in chronically hepatitis C virus-infected individuals lack a virus-induced mutation signature in the TP53, CTNNB1, and BCL6 genes","volume":"87","author":"Tucci","year":"2013","journal-title":"J Virol"},{"issue":"2","key":"2019111703295250700_B35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"key":"2019111703295250700_B36","doi-asserted-by":"crossref","first-page":"638185","DOI":"10.1155\/2012\/638185","article-title":"Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy","volume":"2012","author":"Arcaini","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"6","key":"2019111703295250700_B37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2036.2005.02395.x","article-title":"Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection","volume":"21","author":"Gisbert","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"2019111703295250700_B38","doi-asserted-by":"crossref","first-page":"vi144","DOI":"10.1093\/annonc\/mdt343","article-title":"Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Zucca","year":"2013","journal-title":"Ann Oncol"},{"issue":"10","key":"2019111703295250700_B39","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2013-10-532895","article-title":"B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins","volume":"123","author":"Ng","year":"2014","journal-title":"Blood"},{"key":"2019111703295250700_B40","doi-asserted-by":"crossref","first-page":"980942","DOI":"10.1155\/2012\/980942","article-title":"HCV and lymphoproliferation","volume":"2012","author":"Zignego","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"2","key":"2019111703295250700_B41","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol"},{"issue":"20","key":"2019111703295250700_B42","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMra1213651","article-title":"Current and future therapies for hepatitis C virus infection","volume":"368","author":"Liang","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111703295250700_B43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cncr.11893","article-title":"Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles","volume":"100","author":"Arcaini","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"2019111703295250700_B44","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","article-title":"Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience","volume":"23","author":"Vallisa","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111703295250700_B45","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann Oncol"},{"issue":"4","key":"2019111703295250700_B46","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"11","key":"2019111703295250700_B47","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.3748\/wjg.v20.i11.2771","article-title":"Challenges in managing hepatitis C virus infection in cancer patients","volume":"20","author":"Borchardt","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"11","key":"2019111703295250700_B48","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4254\/wjh.v3.i11.278","article-title":"Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma","volume":"3","author":"Pellicelli","year":"2011","journal-title":"World J Hepatol"},{"issue":"24","key":"2019111703295250700_B49","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2010-06-289231","article-title":"Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis","volume":"116","author":"Ennishi","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111703295250700_B50","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1182\/blood-2006-08-041525","article-title":"Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease","volume":"109","author":"Lake-Bakaar","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111703295250700_B51","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","article-title":"Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients","volume":"57","author":"Mahale","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"2019111703295250700_B52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.21564","article-title":"Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas","volume":"85","author":"Arcaini","year":"2010","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111703295250700_B53","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jhep.2008.06.025","article-title":"Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma","volume":"49","author":"La Mura","year":"2008","journal-title":"J Hepatol"},{"issue":"9","key":"2019111703295250700_B54","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/bmt.2011.238","article-title":"Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy","volume":"47","author":"Ljungman","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111703295250700_B55","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/sj.leu.2403443","article-title":"Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas","volume":"18","author":"Kelaidi","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"2019111703295250700_B56","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2008.07565.x","article-title":"Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas","volume":"145","author":"Mazzaro","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111703295250700_B57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood-2004-05-1711","article-title":"Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?","volume":"105","author":"Saadoun","year":"2005","journal-title":"Blood"},{"issue":"21","key":"2019111703295250700_B58","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMe1403619","article-title":"Therapy of hepatitis C\u2013back to the future","volume":"370","author":"Liang","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111703295250700_B59","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/590\/1249468\/bep00114000590.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/590\/1249468\/bep00114000590.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T08:45:39Z","timestamp":1717577139000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2014\/1\/590\/20297\/Hepatitis-C-virusassociated-Bcell-nonHodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2014.1.590","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}